Akt inhibitors: mechanism of action and implications for anticancer therapeutics

被引：31
作者：
Bhutani, Jaikrit [1 ]
Sheikh, Asfandyar [2 ,4 ]
Niazi, Asfandyar Khan [3 ]
机构：
[1] Post Grad Inst Med Sci, Rohtak, Haryana, India
[2] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan
[3] Shifa Coll Med, Islamabad, Pakistan
[4] Pakistan Res Evolut Sci Soc, Karachi 74200, Pakistan
来源：
INFECTIOUS AGENTS AND CANCER | 2013年 / 8卷
关键词：
SIGNAL-TRANSDUCTION; PROSTATE-CANCER; CELL-SURVIVAL; KINASE; GROWTH; CARCINOMAS; EXPRESSION; ONCOGENE; PATHWAY; GLIOBLASTOMAS;
D O I：
10.1186/1750-9378-8-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in combination with other anticancer drugs could be useful for combating drug resistance and improving response. Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to lead to newer drug development and use.
引用
收藏
页数：4
相关论文
共 36 条
  • [1] Cell survival and metastasis regulation by Akt signaling in colorectal cancer
    Agarwal, Ekta
    Brattain, Michael G.
    Chowdhury, Sanjib
    [J]. CELLULAR SIGNALLING, 2013, 25 (08) : 1711 - 1719
  • [2] The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation
    Barnett, SF
    Bilodeau, MT
    Lindsley, CW
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) : 109 - 125
  • [3] MOLECULAR ALTERATIONS OF THE AKT2 ONCOGENE IN OVARIAN AND BREAST CARCINOMAS
    BELLACOSA, A
    DEFEO, D
    GODWIN, AK
    BELL, DW
    CHENG, JQ
    ALTOMARE, DA
    WAN, MH
    DUBEAU, L
    SCAMBIA, G
    MASCIULLO, V
    FERRANDINA, G
    PANICI, PB
    MANCUSO, S
    NERI, G
    TESTA, JR
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 64 (04) : 280 - 285
  • [4] Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
    Blake, James F.
    Xu, Rui
    Bencsik, Josef R.
    Xiao, Dengming
    Kallan, Nicholas C.
    Schlachter, Stephen
    Mitchell, Ian S.
    Spencer, Keith L.
    Banka, Anna L.
    Wallace, Eli M.
    Gloor, Susan L.
    Martinson, Matthew
    Woessner, Richard D.
    Vigers, Guy P. A.
    Brandhuber, Barbara J.
    Liang, Jun
    Safina, Brian S.
    Li, Jun
    Zhang, Birong
    Chabot, Christine
    Do, Steven
    Lee, Leslie
    Oeh, Jason
    Sampath, Deepak
    Lee, Brian B.
    Lin, Kui
    Liederer, Bianca M.
    Skelton, Nicholas J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (18) : 8110 - 8127
  • [5] AKT2, A PUTATIVE ONCOGENE ENCODING A MEMBER OF A SUBFAMILY OF PROTEIN-SERINE THREONINE KINASES, IS AMPLIFIED IN HUMAN OVARIAN CARCINOMAS
    CHENG, JQ
    GODWIN, AK
    BELLACOSA, A
    TAGUCHI, T
    FRANKE, TF
    HAMILTON, TC
    TSICHLIS, PN
    TESTA, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (19) : 9267 - 9271
  • [6] Amplification of AKT2 in human pancreatic cancer cells and inhibition of ATK2 expression and tumorigenicity by antisense RNA
    Cheng, JQ
    Ruggeri, B
    Klein, WM
    Sonoda, G
    Altomare, DA
    Watson, DK
    Testa, JR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (08) : 3636 - 3641
  • [7] ClinicalTrials.gov, STUD INV AKT INH GSK
  • [8] ClinicalTrials.gov, OP LAB PHAS 2 STUD O
  • [9] Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ
    Garofalo, RS
    Orena, SJ
    Rafidi, K
    Torchia, AJ
    Stock, JL
    Hildebrandt, AL
    Coskran, T
    Black, SC
    Brees, DJ
    Wicks, JR
    McNeish, JD
    Coleman, KG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) : 197 - 208
  • [10] AT7867 Is a Potent and Oral Inhibitor of AKT and p70 S6 Kinase That Induces Pharmacodynamic Changes and Inhibits Human Tumor Xenograft Growth
    Grimshaw, Kyla M.
    Hunter, Lisa-Jane K.
    Yap, Timothy A.
    Heaton, Simon P.
    Walton, Mike I.
    Woodhead, Steven J.
    Fazal, Lynsey
    Reule, Matthias
    Davies, Thomas G.
    Seavers, Lisa C.
    Lock, Victoria
    Lyons, John F.
    Thompson, Neil T.
    Workman, Paul
    Garrett, Michelle D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2010, 9 (05) : 1100 - 1110
1234